featured
Lack of Cost-Effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cost-Effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
JAMA 2016 Aug 16;316(7)743-753, DS Kazi, AE Moran, PG Coxson, J Penko, DA Ollendorf, SD Pearson, JA Tice, D Guzman, K Bibbins-DomingoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.